About UsNewsShop
Fighting hereditary breast and ovarian cancer
Information & Research
| More

NCT00989651

Carboplatin, Paclitaxel, Bevacizumab, and ABT-888 in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Study identifier: NCT00989651
Full study details on clinicaltrials.gov

Name of PARP Inhibitor used in study:

Veliparib (Abbvie)

Eligibility:

  • Histologically confirmed newly diagnosed ovarian epithelial, fallopian tube, or primary peritoneal cancer stage II-IV. More than 5 years since prior chemotherapy for abdominal or pelvic tumor, (prior chemotherapy for localized breast cancer allowed if more than 3 years ago and patient is free of metastatic disease)
  • Stage II-IV disease defined surgically with either optimal (≤ 1 cm) or suboptimal residual disease
    Has undergone initial surgery for diagnosis, staging, and cytoreduction within the past 1-12 weeks

Type of study:

Phase I

Treatment:

Patients are randomized to one of two groups. 

  • The first group receives paclitaxel, carboplatin, and bevacizumab on day one, Veliparib twice daily for 21 days, treatment repeats for 16 courses.
  • The second group receives carboplatin, and bevacizumab on day one, paclitaxel once a week, and Veliparib twice daily for 21 days, treatment repeats for 16 courses

Study sites:

Colorado
Aurora
University of Colorado Cancer Center - Anschutz Cancer Pavilion
Contact: Susan A. Davidson 720-848-0650

Georgia
Augusta
Georgia Health Sciences University
Augusta, Georgia, United States, 30912
Contact: Sharad A. Ghamande 706-721-1663 cancer@georgiahealth.edu

Iliinois
Chicago
University of Chicago Comprehensive Cancer Center
Contact: Seiko D. Yamada 773-834-7424

Iowa
Iowa City
University of Iowa Hospitals and Clinics
Contact: Koen DeGeest 800-237-1225

Maryland
Baltimore
Johns Hopkins University Recruiting
Contact: Deborah K. Armstrong 410-955-8804 jhcccro@jhmi.edu

Missouri
St. Louis
Washington University School of Medicine
Contact: David G. Mutch 800-600-3606 info@ccadmin.wustl.edu

New York
New York
Memorial Sloan Kettering Cancer Center
Contact: Katherine M. Bell-McGuinn 212-639-7202

Ohio
Cleveland
Case Western Reserve University
Contact: Steven E. Waggoner 800-641-2422

Cleveland
Cleveland Clinic Foundation
Contact: Steven E. Waggoner 800-641-2422

Cleveland
MetroHealth Medical Center
Contact: Peter G. Rose 866-223-8100

Mayfield Heights
Hillcrest Hospital Cancer Center Recruiting
Contact: Steven E. Waggoner 800-641-2422

Oklahoma
Oklahoma City

University of Oklahoma Health Sciences Center
Contact: Robert S. Mannel 405-271-4272 julie-traylor@ouhsc.edu

Pennsylvania
Philadelphia
Fox Chase Cancer Center Recruiting
Contact: Lainie P. Martin 215-728-4790

Rhode Island
Providence
Women and Infants Hospital Recruiting
Contact: Carolyn K. McCourt 401-274-1122

Virginia
Charlottesville
University of Virginia
Contact: Linda R. Duska 434-243-6143
Principal Investigator: Linda R. Duska

Richmond
Virginia Commonwealth University Recruiting
Contact: Andrew Poklepovic 804-628-1939

Page updated 06/09/13


Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.

Privacy Policy | Sitemap | Contact Us

Morphtek

This site has been made possible by a generous grant from Morphotek.


Web design by Rareheron Web Design

copyright © FORCE: Facing Our Risk of Cancer Empowered, Inc.  •  info@facingourrisk.org